about
Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesisNoninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosisContribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors.Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted EffectsDMSO increases radioiodination yield of radiopharmaceuticals.
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Radiotargeting agents for cancer therapy.
@ast
Radiotargeting agents for cancer therapy.
@en
type
label
Radiotargeting agents for cancer therapy.
@ast
Radiotargeting agents for cancer therapy.
@en
prefLabel
Radiotargeting agents for cancer therapy.
@ast
Radiotargeting agents for cancer therapy.
@en
P2860
P356
P1476
Radiotargeting agents for cancer therapy.
@en
P2093
Amin I Kassis
P2860
P304
P356
10.1517/17425247.2.6.981
P407
P577
2005-11-01T00:00:00Z